Live price temporarily unavailable.
Kiniksa Pharmaceuticals International (KNSA) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Growth (year over year) | — | — | — | — | — | +471.2% | +22.7% | +56.6% | +60.1% |
| Gross profit | — | — | — | — | $29.4M | $197.3M | $236.9M | $362.3M | $599.9M |
| Gross margin | — | — | — | — | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating income | −$65.4M | −$108.2M | −$170.0M | −$157.4M | −$156.6M | $9.77M | −$25.2M | −$45.6M | $77.2M |
| Operating margin | — | — | — | — | −406.4% | 4.4% | −9.3% | −10.8% | 11.4% |
| Net income | −$64.9M | −$103.2M | −$161.9M | −$161.4M | −$157.9M | $183.4M | $14.1M | −$43.2M | $59.0M |
| Net margin | — | — | — | — | −409.7% | 83.3% | 5.2% | −10.2% | 8.7% |
| EPS (diluted) | −$35.85 | −$3.49 | −$2.99 | −$2.61 | −$2.30 | $2.60 | $0.20 | −$0.60 | $0.75 |
| Balance sheet | |||||||||
| Cash and equivalents | $45.6M | $72.0M | $46.9M | $114.0M | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M |
| Total assets | $47.5M | $322.0M | $254.5M | $349.5M | $232.8M | $459.7M | $526.3M | $580.6M | $763.6M |
| Total liabilities | $17.4M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142.1M | $196.0M |
| Shareholders' equity | −$89.7M | $279.3M | $225.4M | $311.9M | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M |
| Cash flow | |||||||||
| Operating cash flow | −$50.2M | −$81.0M | −$158.4M | −$136.5M | −$126.3M | $5.81M | $13.3M | $25.7M | $138.0M |
| Capital expenditure | $69.0K | $5.29M | $3.20M | $283.0K | $415.0K | $105.0K | $130.0K | $277.0K | $1.57M |
| Free cash flow | −$50.3M | −$86.3M | −$161.6M | −$136.8M | −$126.7M | $5.70M | $13.2M | $25.4M | $136.4M |
| Dividends paid | $0 | $0 | — | — | — | — | — | — | — |
| Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $108.6M | $112.2M | $122.5M | $137.8M | $156.8M | $180.9M | $202.1M | $214.3M |
| Growth (year over year) | +52.0% | +67.4% | +46.9% | +72.5% | +44.3% | +61.2% | +65.0% | +55.5% |
| Gross profit | $96.3M | $92.1M | $104.6M | $119.9M | $138.2M | $160.6M | $181.2M | $193.5M |
| Gross margin | 88.7% | 82.1% | 85.4% | 87.0% | 88.1% | 88.8% | 89.6% | 90.3% |
| Operating income | −$117.0K | −$9.66M | −$19.3M | $13.3M | $20.2M | $24.0M | $19.8M | $29.3M |
| Operating margin | −0.1% | −8.6% | −15.7% | 9.6% | 12.9% | 13.3% | 9.8% | 13.7% |
| Net income | −$3.91M | −$12.7M | −$8.89M | $8.54M | $17.8M | $18.4M | $14.2M | $22.6M |
| Net margin | −3.6% | −11.3% | −7.3% | 6.2% | 11.4% | 10.2% | 7.0% | 10.5% |
| EPS (diluted) | −$0.06 | −$0.18 | −$0.11 | $0.11 | $0.23 | $0.23 | $0.18 | $0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $99.3M | $97.4M | $183.6M | $157.1M | $192.0M | $174.9M | $165.6M | $190.0M |
| Total assets | $542.4M | $555.3M | $580.6M | $599.3M | $661.1M | $712.3M | $763.6M | $825.3M |
| Total liabilities | $107.3M | $118.3M | $142.1M | $141.8M | $166.1M | $176.9M | $196.0M | $219.6M |
| Shareholders' equity | $435.1M | $437.0M | $438.4M | $457.5M | $495.0M | $535.4M | $567.6M | $605.7M |
| Cash flow | ||||||||
| Operating cash flow | $5.17M | −$2.24M | $18.8M | $22.3M | $28.1M | $33.7M | $53.9M | $50.2M |
| Capital expenditure | $0 | $0 | $193.0K | $99.0K | $165.0K | $671.0K | $633.0K | $161.0K |
| Free cash flow | $5.17M | −$2.24M | $18.6M | $22.2M | $27.9M | $33.0M | $53.3M | $50.0M |
From Kiniksa Pharmaceuticals International's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Kiniksa Pharmaceuticals International in our feed yet.